Abstract
Asherman Syndrome (AS) is defined by presence of intrauterine adhesions, due to the loss of endometrial stem cells. CD133+ bone marrow-derived stem cells (BMDSCs) contribute to human endometrium regeneration and represent an advanced cell therapy to treat this disease. Our aim is to describe the short-term and long term engraftment as well as safety and Mechanisms of Action (MoA) of pure and stable population of human CD133+ cells in a model of AS with athymic rats.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
